Biotech Finances Highlights RebrAIn’s Successful Funding Round for supervised AI Neurosurgery

We are pleased to announce that Biotech Finances has featured RebrAIn in their recent article. RebrAIn has successfully completed a €3.7 million funding round led by Karista, with participation from Nouvelle Aquitaine Co-Investissement and existing investors.

Our CE-marked and FDA-cleared SaaS solution revolutionizes neurosurgical procedures by using advanced AI algorithms and MRI sequences to provide optimal targets for electrode placement in Deep Brain Stimulation (DBS) surgeries. The funds will support team expansion and international commercialization of our precision AI-driven neurosurgery solutions.

Read the article, in french, here.

An English translation by Google is available here.

Our latest public updates

Rebrain unveils its identity: a strong vision for the future of assisted neurosurgery

May 21, 2026

At Rebrain, innovation has never been an end in itself. It has always been a means to improve the precision of neurosurgical procedures and to have a concrete impact on patients’ lives. Today, we are reaching a new stage of our development with the official launch of...

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Jan 5, 2026

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...

Rebrain publishes OPTIVIM trial results in Neurosurgery

Dec 5, 2025

An innovative and automated method RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target,...

« Older Entries